HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 22, 2015 (HealthDay News) -- Naturally occurring monoclonal antibodies show potential for treatment of neurologic diseases, according to a review published online Sept. 21 in JAMA Neurology.
Bharath Wootla, Ph.D., from the Mayo Clinic in Rochester, Minn., and colleagues reviewed the role of monoclonal, naturally occurring antibodies (NAbs) as novel therapeutic molecules for neurologic disorder treatment.
The researchers note that injury such as trauma, ischemia, infection, inflammation, and neurodegeneration results in irreversible central nervous system (CNS) damage. Such injury often results in a pervasive inhibitory microenvironment, which can prevent regeneration. Identifying molecules with high potency in animal models is a common targeted drug delivery strategy. However, approaches frequently fail in the clinical setting due to lack of efficacy in human disease or high incidence of toxic effects. Identification of NAbs in humans is an alternative approach; these therapeutic molecules have potential physiologic function without toxic effects. Recombinant, autoreactive, natural human immunoglobulin M (IgM) antibodies directed against oligodendrocytes or neurons were developed, which had therapeutic potential for CNS repair. A successful phase 1 clinical trial was performed with one of these molecules, recombinant HIgM22, which was directed against myelin and oligodendrocytes with the goal of promoting remyelination in multiple sclerosis, with no indication of toxic effects.
"This class of antibodies represents a unique source from which to develop a new class of disease-modifying therapies," the authors write.
Patents for antibodies that promote remyelination and CNS repair are issued and owned by the Mayo Clinic.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 22, 2015